Methods and compounds for the treatment or prevention of severe influenza
AssigneePoolbeg Pharma (UK) Limited
InventorsPaul Andrew Whittaker, Neil Edward Torbett
Life of this patent
Estimating the term…
Abstract
A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza may be characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.
Claims19
A method of treating a human patient at risk of severe influenza after an immune response has been triggered, said method comprising administering to the patient a p38 MAP kinase inhibitor, wherein the p38 MAP kinase inhibitor inhibits the release of pro-inflammatory mediators from endothelial cells and inhibits the release of pro-inflammatory cytokines from immune cells.
A method of treating hypercytokinemia characteristic of severe influenza, the method comprising administering to the patient a therapeutically effective amount of a p38 MAP kinase inhibitor;
- wherein the p38 MAP kinase inhibitor inhibits the release of pro-inflammatory mediators from endothelial cells and inhibits the release of pro-inflammatory cytokines from immune cells.
Dependencies are inferred from the claim text.